Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
Methods for manipulating phagocytosis mediated by CD47
US9493575B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9493575-B2 |
| Application number | US-201514799328-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 14, 2015 |
| Priority date | Jan 15, 2008 |
| Publication date | Nov 15, 2016 |
| Grant date | Nov 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of increasing the elimination of hematopoietic cancer cells by phagocytosis in a human subject comprising: administering to the subject a first monoclonal antibody specific for a marker of the cancer cells other than CD47 which comprises an Fc region capable of engaging Fc receptors on phagocytic cells to signal phagocytosis of the hematopoietic cancer cells, and a second monoclonal antibody that prevents the binding of CD47 to SIRP alpha and increases phagocytosis of the hematopoietic cancer cells by the first antibody. 2. The method of claim 1 , wherein the first monoclonal antibody is an entire humanized, chimeric or human antibody. 3. The method of claim 1 , wherein the first monoclonal antibody specifically binds to an AML stem cell surface marker. 4. The method of claim 1 , wherein the hematopoietic cancer cells are AML cells. 5. The method of claim 1 , wherein the second monoclonal antibody is an antibody that specifically binds to CD47. 6. The method of claim 1 , wherein the second monoclonal antibody is an entire antibody. 7. The method of claim 1 , wherein the second monoclonal antibody is a binding fragment.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9493575B2 cover?
- Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.
- Who is the assignee on this patent?
- Univ Leland Stanford Junior
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).